Objective:To investigate the clinical effect of free medial sural artery perforator flap (MSAP) in repairing skin and soft tissue defects of hand and foot.Methods:The clinical data of patients with soft tissue defects of hand and foot who were treated by the free MSAP in Xuzhou Renci Hospital from January 2017 to December 2019 were analyzed retrospectively. When repairing the wound of the foot, the donor site was harvested from the ipsilateral lower limb; when repairing the wound of the hand, the donor site was harvested from the ipsilateral or contralateral lower limb. Regular follow-up was carried out through outpatient reexamination, WeChat and telephone. The hand scoring criterion was the upper extremity functional evaluation standard set up by the Chinese Society of Hand Surgery of the Chinese Medical Association; the foot scoring criterion was the Maryland score system.Results:All 10 patients were involved, including 5 males and 5 females. The mean age was 44.8 years (ranging from 16 to 56 years). There were 8 cases of hand wounds and 2 cases of and foot wounds. The MSAP size was 4.0 cm×7.0 cm-5.0 cm×14.0 cm. The lower leg donor site was closed primarily. The cutaneous nerves were anastomosed in seven cases. All flaps survived in 10 patients and primary healing after the operation. One flap had a vascular crisis after the operation and survived after the vascular exploratory operation. Nine cases were followed up for 6-12 months; the mean follow-up time was 8 months. the MSAP was in good shape, the sensation of the flap recovered to grade S2-S3, and the two-point discrimination was 7-9 mm. The hand and foot function returned to normal. The flap in the weight-bearing area was not broken. The movement and sensation of the lower limbs in the donor area were normal without dysfunction. At the last follow-up, hand function was evaluated: 6 cases were excellent and 1 case was good; the evaluation of foot function was excellent in 2 cases. One patient was lost to follow-up.Conclusions:The free MSAP does not damage the main blood vessels; the perforating branches are relatively constant, the vascular pedicle is long, and the subcutaneous fat layer is thin. The effect of repairing the wound of hand and foot is good.

Objective:To investigate the clinical effect of free medial sural artery perforator flap (MSAP) in repairing skin and soft tissue defects of hand and foot.Methods:The clinical data of patients with soft tissue defects of hand and foot who were treated by the free MSAP in Xuzhou Renci Hospital from January 2017 to December 2019 were analyzed retrospectively. When repairing the wound of the foot, the donor site was harvested from the ipsilateral lower limb; when repairing the wound of the hand, the donor site was harvested from the ipsilateral or contralateral lower limb. Regular follow-up was carried out through outpatient reexamination, WeChat and telephone. The hand scoring criterion was the upper extremity functional evaluation standard set up by the Chinese Society of Hand Surgery of the Chinese Medical Association; the foot scoring criterion was the Maryland score system.Results:All 10 patients were involved, including 5 males and 5 females. The mean age was 44.8 years (ranging from 16 to 56 years). There were 8 cases of hand wounds and 2 cases of and foot wounds. The MSAP size was 4.0 cm×7.0 cm-5.0 cm×14.0 cm. The lower leg donor site was closed primarily. The cutaneous nerves were anastomosed in seven cases. All flaps survived in 10 patients and primary healing after the operation. One flap had a vascular crisis after the operation and survived after the vascular exploratory operation. Nine cases were followed up for 6-12 months; the mean follow-up time was 8 months. the MSAP was in good shape, the sensation of the flap recovered to grade S2-S3, and the two-point discrimination was 7-9 mm. The hand and foot function returned to normal. The flap in the weight-bearing area was not broken. The movement and sensation of the lower limbs in the donor area were normal without dysfunction. At the last follow-up, hand function was evaluated: 6 cases were excellent and 1 case was good; the evaluation of foot function was excellent in 2 cases. One patient was lost to follow-up.Conclusions:The free MSAP does not damage the main blood vessels; the perforating branches are relatively constant, the vascular pedicle is long, and the subcutaneous fat layer is thin. The effect of repairing the wound of hand and foot is good.

Objective:To analyze the molecular characteristics of hemagglutinin-neuraminidase (HN) gene of human parainfluenza virus type 3 (HPIV3) among the cases with acute respiratory tract infection (ARI) in Henan Province.Methods:Nasal/throat swab samples collected from patients with severe acute respiratory tract infection (SARI) in Luohe and patients with influenza-like illness (ILI) in Zhengzhou were used in this study. HPIV nucleic acids in the samples were detected using real-time fluorescent PCR. HPIV3-positive samples were subjected to RT-PCR for the amplification of HN genes and the sequences were analyzed with Sanger method. CExpress and MEGA7.0 software were used for sequences editing, evolution tree construction and gene sequence analysis.Results:A total of 374 throat swab samples collected form ARI cases in Luohe and Zhengzhou were tested and 20 (5.3%) of them were positive for HPIV3. Eighteen HPIV3 HN gene sequences were successfully amplified and all belonged to C3 subgroups, including 16 sequences of C3f genotype and two sequences of C3a genotype. The 18 HN gene sequences shared the homology of 97.6%-100.0% in nucleotide and 99.3%-100.0% in amino acid, but the differences between them and the prototype strain Wash/47885/57 were significant. There were 12 amino acid mutations shared by them, including four function-related mutations (H295Y, I391V, D556N and I53T). There were no significant differences in the nucleotide or amino acid sequences as compared with the epidemic strain of China/BCH4210A/2014.Conclusions:The C3f and C3a branches of HPIV3 were the epidemic genotypes in Henan Province in recent years and a local circulating prevalence might be established. Continuous and in-depth monitoring of HPIV3 C3 subtype would be of great significance for the prevention and control of HPIV3-associated diseases.

Cancer stem cells (CSCs), a subpopulation of tumor cells, have self-renewal and multi-lineage differentiation abilities that play an important role in cancer initiation, maintenance, and metastasis. An accumulation of evidence indicates that CSCs can cause conventional therapy failure and cancer recurrence because of their treatment resistance and self-regeneration characteristics. Therefore, approaches that specifically and efficiently eliminate CSCs to achieve a durable clinical response are urgently needed. Currently, treatments with chimeric antigen receptor-modified T (CART) cells have shown successful clinical outcomes in patients with hematologic malignancies, and their safety and feasibility in solid tumors was confirmed. In this review, we will discuss in detail the possibility that CART cells inhibit CSCs by specifically targeting their cell surface markers, which will ultimately improve the clinical response for patients with various types of cancer. A number of viewpoints were summarized to promote the application of CSC-targeted CART cells in clinical cancer treatment. This review covers the key aspects of CSC-targeted CART cells against cancers in accordance with the premise of the model, from bench to bedside and back to bench.
Humans ; Molecular Targeted Therapy ; methods ; Neoplasms ; immunology ; pathology ; therapy ; Neoplastic Stem Cells ; pathology ; Receptors, Chimeric Antigen ; metabolism ; T-Lymphocytes ; immunology ; metabolism ; Translational Medical Research

This phase I clinical trial (NCT01935843) is to evaluate the safety, feasibility, and activity of chimeric antigen receptor-engineered T cell (CART) immunotherapy targeting human epidermal growth factor receptor 2 (HER2) in patients with advanced biliary tract cancers (BTCs) and pancreatic cancers (PCs). Eligible patients with HER2-positive (>50%) BTCs and PCs were enrolled in the trial. Well cultured CART-HER2 cells were infused following the conditioning treatment composed of nab-paclitaxel (100-200 mg/m) and cyclophosphamide (15-35 mg/kg). CAR transgene copy number in the peripheral blood was serially measured to monitor the expansion and persistence of CART-HER2 cells in vivo. Eleven enrolled patients received 1 to 2-cycle CART-HER2 cell infusion (median CAR T cell 2.1 × 10/kg). The conditioning treatment resulted in mild-to-moderate fatigue, nausea/vomiting, myalgia/arthralgia, and lymphopenia. Except one grade-3 acute febrile syndrome and one abnormal elevation of transaminase (>9 ULN), adverse events related to the infusion of CART-HER2 cells were mild-to-moderate. Post-infusion toxicities included one case of reversible severe upper gastrointestinal hemorrhage which occurred in a patient with gastric antrum invaded by metastasis 11 days after the CART-HER2 cell infusion, and 2 cases of grade 1-2 delayed fever, accompanied by the release of C-reactive protein and interleukin-6. All patients were evaluable for assessment of clinical response, among which 1 obtained a 4.5-months partial response and 5 achieved stable disease. The median progression free survival was 4.8 months (range, 1.5-8.3 months). Finally, data from this study demonstrated the safety and feasibility of CART-HER2 immunotherapy, and showed encouraging signals of clinical activity.
Aged ; Biliary Tract Neoplasms ; immunology ; therapy ; Female ; Humans ; Immunotherapy, Adoptive ; Male ; Middle Aged ; Pancreatic Neoplasms ; immunology ; therapy ; Receptor, ErbB-2 ; immunology ; Receptors, Chimeric Antigen ; immunology ; T-Lymphocytes ; immunology